Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin

Inclusion Criteria: * Men and women ages 18 to 70 years (inclusive) at the time of screening with hyperlipidemia * Body mass index (BMI) ≥18 and ≤ 35 kg/m\^2 at the time of screening * Low-density lipoprotein cholesterol (LDL-C) level of 70-220 mg/dL (inclusive) at screening as measured by direct assay * For Cohorts 1-5: On a stable dose of rosuvastatin (Crestor) \< 40 mg/day, atorvastatin (Lipitor) \< 80 mg/day, or simvastatin (Zocor) 20-80 mg/day for ≥ 1 month prior to enrollment and expected to remain on this dose for the remainder of the study * For Cohort 6: On a stable dose of rosuvastatin (Crestor) 40 mg/day or atorvastatin (Lipitor) 80 mg/day for ≥ 1 month prior to enrollment and expected to remain on this dose for the remainder of the study * For Cohort 7: Diagnosis of heterozygous familial hypercholesterolemia, based on a score of ≥ 9 points using the World health Organization (WHO) criteria Exclusion Criteria: * Diagnosis of homozygous familial hypercholesterolemia * History of heart failure, coronary artery bypass graft, or cardiac arrhythmia * History of acute coronary syndrome (e.g. myocardial infarction, hospitalization for unstable angina) or percutaneous coronary intervention, within 12 months prior to enrollment * Planned cardiac surgery or revascularization * Known aortic, peripheral vascular or cerebrovascular disease (including history of stroke or transient ischemic attack) * Diabetes mellitus with any of the following: 1. known microvascular or macrovascular disease 2. HbA1c \> 8.0% at screening 3. use of any hypoglycemic medication other than metformin * Uncontrolled hypertension (systolic blood pressure ≥ 150 or diastolic blood pressure ≥ 90 mmHg) either on or off therapy at screening or at baseline